In breast cancer MDA-MB-453 cells, the treatment with either the mTOR inhibitor, everolimus (10 nM) or the Akt inhibitor, AZD5363 (1 μM) significantly up-regulated KCa1.1 transcription (Figures 6C,D). Here, MTOR is linked to breast carcinoma.